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Objectives: Fluconazole-resistant oropharyngeal candidiasis (OPC) is a rapidly growing problem in HIV-infected 
patients. To better understand the pathogenesis of fluconazole resistance in this setting, asymptomatic candidal carriage 
was determined by means of oral swabs regularly performed in all patients without clinical signs of OPC seen at our 
HIV outpatient clinic. Controls were 204 asymptomatic healthcare workers without previous exposure to  fluconazole. 
Methods: Swabs were plated on three solid media and put in a Sabouraud broth. Phenotypically different colonies were 
identified to the species level. Susceptibility t o  fluconazole was determined using a disk diffusion test with 50 k g  
fluconazole disks on yeast nitrogen agar, with a cut-off value of 25 mm. 
Results: Swabs were performed in 538 consecutive HIV-positive patients, of whom 216 (40%) had had prior episode(s) 
of OPC and/or were previously exposed to fluconazole. Yeasts were grown in 418/538 HIV-positive patients (78%), 
compared to  57/204 controls (28%) (p<0.05). In HIV-positive patients, yeasts were grown in 189/216 (88%) of those with 
past fluconazole exposure, and in 229/322 (71%) without exposure (pc0.05). A total of 589 isolates were grown in  the 
538 HIV-positive patients (451 C. albicans, 88 C. glabrata, 22 C. tropicalis, 11 C. krusei, and 17 isolates from 12 other 
species). Resistance to fluconazole was present in 121/589 (21%) Candida species isolates in HIV-positive patients and 
in 2/59 (3%) in controls. Among C. albicans isolates, there were 18 fluconazole-resistant strains in HIV-positive patients 
(4%) and none in controls. 
Conclusions: Using sensitive culture methods, oral yeast colonization was detected significantly more frequently in 
HIV-infected patients (78%) than in  a control group of HIV-negative persons (28%). In addition, yeast colonization was 
quantitatively more important in patients with lower CD4' lymphocyte counts and for those who had been exposed to  
fluconazole for episode(s) of OPC. Fluconazole-resistant C. albicans isolates were observed only in  HIV-positive patients, 
and all patients (17/18) for whom this information could be ascertained had had prior exposure to  fluconazole.. 
Key words: Oropharyngeal candidiasis, fluconazole, resistance, Candida albicans, Candida spp., yeast carriage 
Oropharyngeal candidiasis (OPC) is the most frequent 
HIV-related infection, and develops at some time 
during the course of HIV illness in up to '30% of the 
patients [l].  In this context, the efficacy and the safety 
of fluconazole have been shown to be superior to those 
of ketoconazole 121, and fluconazole has become the 
regimen of choice for therapy of OPC in many HIV 
outpatient clinics. However, we [3,4] and others [5-7] 
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recently observed an increasing number of OPC 
episodes clinically not responding to fluconazole 
therapy. Candida albicarzr strains isolated in patients with 
clinical failure have been shown to have a decreased 
susceptibility t o  fluconazole [3,6,7J. Patients with 
fluconazole-resistant OPC have been previously 
exposed significantly more often to fluconazole than 
patients whose episodes of O P C  responded to the 
drug [4,6]. Moreover, using genotyping of consecutive 
C. alhicans isolates cultured in the same patients, we 
showed that resistance was probably acquired undcr 
fluconazole exposure by the initial susceptible C. albicans 
isolate [4], a mechanism often - but not always - 
observed (for review see Rex et a1 [8J). To confirm and 
extend these observations, we decided to regularly 
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perform oral swabs in all symptomatic or asymptomatic 
patients followed at our HIV outpatient clinic. Data 
obtained in patients without signs of OPC at the time 
of swab collection are presented here. 
M ETH 0 DS 
Patients 
In our institution, patients are followed by the HIV 
outpatient clinic at  least twice a year, irrespective of the 
stage of their HIV infection. The following data were 
prospectively collected at the time of visit and oral 
swabbing: CD4+ lymphocyte count, previous number 
of OPC episodes and antifungal therapy, and clinical 
evidence of active candidiasis. 
Controls 
There were 204 asymptomatic healthcare workers 
without previous exposure to fluconazole. There were 
66 males and 138 females, and the median age was 28 
(range: 16 to 54). 
Microbiology 
Swabs were performed on anterior and posterior 
palatal mucosa in each patient, using a standardized 
procedure. All swabs were plated onto three solid media 
(Sabouraud dextrose agar, chocolate blood agar, 5% 
sheep blood agar) and put into a Sabouraud broth. 
Broths were secondarily plated onto Albicans ID 
selective and differential medium (bioMerieux, Marcy- 
UEtoile, France). Yeasts were identified to genus and 
species level using conventional procedures (germ tube 
test and biotyping) . Fluconazole susceptibility was 
tested with an agar disk diffusion method using yeast 
nitrogen agar with a 50-pg disk of fluconazole. In vitro 
resistance to fluconazole was defined by diameters of 
inhibition < 2 5  mm, which has been shown to cor- 
relate with MIC > 25 p g / d  [3]. Our method has 
shown an excellent correlation with the disk diffusion 
method developed by Troke [9]. 
From February 1993 to June 1994, oral swabs were 
systematically performed in 538 consecutive HIV- 
positive outpatients without clinical evidence of OPC. 
There were 443 males and 95 females. HIV infection 
was acquired through intravenous drug use in 226 
patients, homosexual relations in 167, heterosexual 
relations in 102, and the administration of blood 
products in 27. The route of HIV infection could not 
be determined in 16 cases. The median CD4+ cell 
count was 245/mm3 (range: 1 to 1500). Of  the 538 
patients, 216 (40%) had been previously exposed to 
fluconazole, because of past episode(s) of OPC (214 
patients) or cryptococcal infection (2 patients). 
Oral yeast colonization was detected in 78% of 
HIV-infected patients and in 28% of HIV-negative 
controls (Table 1). Moreover, isolates were retrieved 
from broth culture only in the majority of HIV- 
negative persons (74%) with positive cultures, and grew 
both on primary plates and in broth in most of the 
Table 1 Oral yeast carriage in HIV-infected patients without OPC and in HIV-negative controls: quantitative yeast growth 
characteristics 
HIV-negative HIV-positive P 
Number of subjects 
Oral yeast carriage 
Growth on primary plates 
Growth in broth only 
Mixed culture (2 2 yeast spp.) 
Total number of isolates 
C. albicans 
Other yeasts 
C. glabvata 
C. tropicalis 
C. krusei 
Others 
Fluconazole-resistant isolates 
C. albicans 
Other yeasts 
C. glabvata 
C. tropicalis 
6 krusei 
Others 
57/204 
15 
42 
2 
59 
51 
8 
1 
~ 
~ 
7 
2 
0 
2 
1 
~ 
- 
1 
204 
(28%) 
(26%) 
(4%) 
(86%) 
(3%) 
538 
41 81538 (78%) < 0.05 
309 (74%) < 0.05 
109 
124 (30%) < 0.05 
589 
45 1 (77%) = 0.05 
138 
88 
22 
11 
17 
121 (21%) 
18 
103 
85 
1 
11 
6 
< 0.05 
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HIV-positive patients (74%) with positive cultures 
(Table 1). Rates of oral colonization were 88% in HIV- 
positive patients with past fluconazole exposure and 
71 5%) in HIV-positive patients without exposure. Oral 
yeast colonization was quantitatively more important in 
patients previously exposed to fluconazole, and with 
lower CD4+ lymphocyte counts (Table 2). Fifty-nine 
isolates were recovered in the 57 HIV-negative persons 
with oral yeast colonization: there were 51 C. albicans 
and 8 other yeasts (3 Geofrichurn spp, and C. glabrata, 
C. norvegiensis, C. valida, Sacclzaromyces cerevisiae, Tricho- 
sporoiz capitaturn) (1 each). A total of 589 isolates were 
recovered in the 418 colonized HIV-positive patients 
[451 C. albicans, 88 C. glabruta, 22 C. tropicalis, 11 C. 
krusci, 4 Saccharonzyces cerevisiae, 2 C. pavapsilosis, 2 
Geotrirhum spp., and one isolate each of C. colliculosa, 
C. intermedia, C. k$r, C. lusitaniae, C. norvegiensis, 
Klocckera upiculata, K. apis, Rkodotorula glutinis, R. rubra 
(Table l)] .  Resistance to fluconazole was present in two 
of the 59 isolates in controls, both belonging to species 
with known reduced susceptibility to fluconazole (C. 
glabruta and C. norvegiensis) (Table 1). In the 418 HIV- 
positive patients with oral yeast colonization, there 
were 121 fluconazole-resistant isolates: 103 were of 
species intrinsically less susceptible to the drug (85 
C. glabrata, 11 C. krusei, 3 S.  cerevisiae, and 1 isolate 
each of C. tropicalis, C. novvegiensis, Rhodotorula glutinis 
and K .  nrbra). In addition, there were 18 isolates of C. 
albii-ans that were resistant to fluconazole: prior ex- 
posure to the compound was documented in 17 of 
them and was not assessable in the last patient (Table 2). 
Table 2 Oral yeast carriage in HIV-infected patients: 
quantitative growth and itolate characteristics according to 
previous exposure to fluconazole 
Previous 
flucoiiarolc 
Total exposure 
H IV-p 051 tive 
patients No Yes P 
N~iiiiber O f  SLlbJJECtS i 3 8  322 
Mean CLM' 
ly1nyhocytes 261+10 32421.3 
Oral yeast carriagc 118/538 229/322 
(78%) (71%)) 
Growth on prinixy plate5 309 155 
Growth 111 broth only 109 74 
Mixed culturc 
( 2 2  yc" spp.) 124 69 
Total nuniber of isolates 589 325 
Fluconarole~resistdiit 1 1 1  (21%) 55 (17%) 
c. albrranr 45 1 258 
Fluconazole-rctistait 18" 0 
216 
1801-13 1 0 . 0 5  
189/216 <0.05 
151 <0.05 
(88%) 
35 
55 NS 
261 
193 
66 (25%) < O  05 
17 (8 8%)A <0.05 
' Prior exposition to flucotiazole not assessable In one patient. 
O f  the 189 HIV-infected patients with previous 
exposure to fluconazole who were found to be 
colonized with yeasts, all carried at least one C. alhirans 
isolate (two different C. ulbicans in four patients), with 
or without additional non-C. alhicans yeasts. All patients 
with a C. albicans fluconazole-resistant strain carried it 
in pure culture, whereas the 49 other non-C. albicans 
yeasts resistant to fluconazole (mostly C. glabvata) were 
found in mixed culture with a fluconazole-susceptible 
C. albicans strain. 
DISCUSSION 
Candida organisms are normal inhabitants of the 
oropharyngeal cavity, and isolation rates of yeasts from 
the mouths of healthy individuals have been reported 
to range between 2% and 3796, niainly depending on 
the culture method used [lo]. Oral yeast colonization 
is higher in hospitalized patients, with rates ranging 
from 13% to 76% [ I l l ,  but data in HIV-infected 
patients are limited so far. Sangeorzan et a1 found 84% 
of 92 HIV-infected patients to be colonized, mostly 
(81%) by C. albicans [12]. 
Using sensitive culture methods, we detected oral 
yeast colonization in the mouths of 57 of 204 healthy 
HIV-negative persons (28%), as compared to 418 of 
538 patients at various stages of their HIV infection 
(78%). In addition, yeast colonies were significantly 
more numerous in the latter patients. This observation 
can be explained by several factors, among which are 
the elimination of bacterial coinpetitive flora in HIV- 
positive patients by concurrent antibiotic therapy or 
prophylaxis for opportunistic infections, the fiequcncy 
of infection- or drug-related lesions of oral mucosa, and 
the underlying HIV-related immunodeficiency. Oral 
yeast colonization was quantitatively and qualitatively 
more important in HIV-positive patients who had 
presented prior episode(s) of O K ,  and who had lower 
CD4+ lymphocyte counts. As there is a clear cor- 
relation between CD4+ lymphocyte count and the 
nunibcr of OPC episodes [3,6,13], it was not possible 
to determine the relative importance of these two 
factors. In addition, yeasts usually cannot be eradicated 
under treatment for OPC because of the fungistatic 
effect of azole antifungal drugs and because of the 
persistence of the underlying HIV-associated immuno- 
suppression. Consequently, recurrences are reported in 
50-100% ofthe patients [14,15]. Due to its efficacy and 
safety, fluconazole usually represents the first-line 
therapy for OPC and has been used in over 15 x 10'' 
patients (data on file, Pfizer Inc.). However, chronic 
exposure to fluconazole ha$ been statistically related 
to the development of clinical and microbiological 
resistance to the drug [4,6]. Our work indirectly 
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confirms these observations, since isolates of C. albicuns 
resistant to fluconazole were cultured only in HIV- 
positive patients, all but one of them with known prior 
exposure to fluconazole. 
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